HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences to develop world’s first combination vaccine against shigellosis and typhoid
Mar-04-2025

Zydus Lifesciences is all set to develop world’s first combination vaccine against shigellosis and typhoid. Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine. The project is expected to get underway in March 2025, and is being supported by the Gates Foundation.

Zydus will collaborate with a partner for the research and co-development of a combination vaccine using Zydus’ WHO prequalified Typhoid conjugate vaccine (ZyVac TCV) and Shigella Vaccine from Zydus’ partner. This combination of vaccines, if found successful, will safeguard children against two lethal enteric diseases of global relevance and potentially offer a viable solution in a scenario where childhood immunization schedules are becoming increasingly crowded, expensive, and unsustainable.

Zydus Lifesciences is one of the leading innovations driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products.


  RELATED NEWS >>